Full metadata record
DC FieldValueLanguage
dc.creatorCrespo, G. (Guillermo)-
dc.creatorJiménez-Fonseca, P. (Paula)-
dc.creatorCustodio, A. (Ana)-
dc.creatorLópez, C. (Carlos)-
dc.creatorCarmona-Bayonas, A. (Alberto)-
dc.creatorAlonso, V. (Vicente)-
dc.creatorNavarro, M. (Miguel)-
dc.creatorAller, J. (Javier)-
dc.creatorSevilla, I. (Isabel)-
dc.creatorGrande, E. (Enrique)-
dc.creatorGajate, P. (Pablo)-
dc.creatorAlonso-Gordoa, T. (Teresa)-
dc.creatorMatos, I. (Ignacio)-
dc.creatorCapdevila, J. (Jaume)-
dc.creatorNieto, B. (Beatriz)-
dc.creatorBarriuso, J. (J.)-
dc.date.accessioned2024-02-08T15:16:26Z-
dc.date.available2024-02-08T15:16:26Z-
dc.date.issued2016-
dc.identifier.citationCrespo G, Jiménez-Fonseca P, Custodio A, López C, Carmona-Bayonas A, Alonso V, Navarro M, Aller J, Sevilla I, Grande E, Gajate P, Alonso-Gordoa T, Matos I, Capdevila J, Nieto B, Barriuso J. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncol. 2017 Mar;13(7):615-624. doi: 10.2217/fon-2016-0434. Epub 2016 Nov 2. PMID: 27802780.es_ES
dc.identifier.issn1479-6694-
dc.identifier.urihttps://hdl.handle.net/10171/68934-
dc.description.abstractBackground & methods: Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs). Results: Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7-21.6) and overall survival was 38.3 months (95% CI: 24.6-51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%). Conclusion: This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.subjectCapecitabinees_ES
dc.subjectCarcinoidses_ES
dc.subjectNeuroendocrine tumorses_ES
dc.subjectPancreatic neuroendocrine tumorses_ES
dc.subjectRetrospective studyes_ES
dc.subjectTemozolomidees_ES
dc.titleCapecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experiencees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.2217/fon-2016-0434-
dc.identifier.pmid27802780-

Files in This Item:
File
Articulo2.pdf
Description
Size
1.9 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.